<DOC>
	<DOCNO>NCT00828815</DOCNO>
	<brief_summary>TMC125 class drug call non-nucleoside reverse transcriptase inhibitor ( NNRTIs ) . NNRTIs work block reverse transcriptase , protein HIV need make copy . TMC125 use treatment adult HIV-1 infection . The purpose trial see potential interaction ( change effectiveness drug ) take multiple-dose TMC125 buprenorphine/naloxone together . The trial also assess short-term safety tolerability ( well body handle drug ) TMC125 buprenorphine/naloxone take together .</brief_summary>
	<brief_title>TMC125-TiDP2-C188 : A Phase I , Open-label Trial Investigate Pharmacokinetic Effect Multiple-dose TMC125 Buprenorphine Norbuprenorphine Administered HIV-negative Patients Stable Buprenorphine/Naloxone Maintenance Therapy .</brief_title>
	<detailed_description>This Phase I , open-label ( patient trial doctor know medication take point time trial ) , add-on trial patient stable sublingual ( place mouth tongue disolves ) buprenorphine/naloxone maintenance therapy , investigate potential pharmacokinetic effect multiple-dose TMC125 buprenorphine norbuprenorphine administer buprenorphine/naloxone . The study population consist 16 HIV-negative opioid-dependent patient stable individualized sublingual buprenorphine/naloxone maintenance therapy . Patients first participate 2 week run-in period supervise buprenorphine/naloxone intake . Subsequently , patient receive TMC125 200 mg orally twice daily 14 day add buprenorphine/naloxone treatment . During treatment period Day 1 Day 14 , individualize buprenorphine/naloxone treatment continue co-administration TMC125 . Full pharmacokinetic profile buprenorphine norbuprenorphine determine Days -1 14 24 hour postdose . Full pharmacokinetic profile TMC125 determine Day 14 12 hour postdose . Pharmacodynamic assessment symptom opiate withdrawal excess perform . The short-term safety tolerability assess throughout trial . Patients firstparticipate 2 week run-in period supervise buprenorphine/naloxone intake . Subsequently , patient receive 2 tablet 100 mg TMC125 twice daily 14 day add buprenorphine/naloxone treatment . During treatment period Day 1 Day 14 , individualize buprenorphine/naloxone treatment continue co-administration TMC125 .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18.0 30.0 kg/m2 , extremes include . BMI calculate weight ( kg ) divide square height ( ) Receiving daily buprenorphine/naloxone maintenance therapy stable individualize dose formulate administer sublingual tablet maximum daily dose 16/4 mg buprenorphine/naloxone . Patients use buprenorphine also eligible switch buprenorphine/naloxone minimally 2 week randomization The patient agree change current buprenorphine/naloxone therapy Screening Day 14 include ( switch buprenorphine buprenorphine/naloxone Screening Day 14 allow ) daily observe document buprenorphine/naloxone intake Day 14 Day 15 General medical condition , investigator 's opinion , interfere assessment completion trial . A positive HIV1 HIV2 test Screening Female , except postmenopausal since 2 year , posthysterectomy , posttubal ligation ( without reversal operation ) Evidence current use barbiturate , amphetamine , recreational narcotic drug use ( cocaine , inhalant , stimulant ) , sedative hypnotic ( benzodiazepine ) , excessive alcohol opioids . The drug screen involves analysis amphetamine , barbiturate , benzodiazepine , cocaine opioids Hepatitis A infection ( confirm hepatitis A antibody IgM ) , hepatitis B infection ( confirm hepatitis B surface antigen ) study screen Currently active gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-negative</keyword>
	<keyword>buprenorphine/nalaxone</keyword>
	<keyword>norbuprenorphine</keyword>
	<keyword>opioid-dependent</keyword>
	<keyword>TMC125-TiDP2-C188</keyword>
	<keyword>TMC125-C188</keyword>
	<keyword>TMC125</keyword>
	<keyword>HIV Infections</keyword>
</DOC>